Evotec Se · XETR:EVT
Evotec — Investor Day (April 2021)
87 slides from Evotec's investor day presentation, Apr 20, 2021
Slide 1: The "Vroooooooom" behind Action Plan 2025
The “Vroooooooom” behind Action Plan 2025 The data-driven R&D Autobahn to Cures Evotec SE, Capital Markets Day, April 20th 2021
Slide 2: Cautionary statement regarding forward-looking statements
Cautionary statement regarding forward-looking statements Information set forth in this presentation contains forward-looking statements, which involve a number of risks and uncertainties. All statements other than statements of historical fact are forward-looking statements, which are often indicat
Slide 3: Digital Capital Markets Day: Action Plan 2025 agenda
20 APRIL 2021 AGENDA DIGITAL CAPITAL MARKETS DAY: 08.00 – 08.30 am Action Plan 2025 - The data-driven R&D Autobahn to Cures ACTION PLAN 2025 Our business strategy 08.30 – 08.50 am Data-driven precision medicine Tuesday 20 April 2021 iPSC – Witnessing a new paradigm 8.00 am EST – 10.30 am EST; 2.
Slide 4: Let's talk about Action Plan 2025
Let’s talk about Action Plan 2025 1st Capital markets day 2021 Werner Cord Craig Enno Lanthaler Dohrmann Johnstone Spillner CEO CSO COO CFO Rainer Sandra Dean Thomas Kuhn Lubitz Pettit Hanke Neurosciences iPSC Biotherapeutic Academic Science Partnerships PAGE 4
Slide 5: Action Plan 2025 – The data-driven R&D Autobahn to Cures
PAGE 5
Slide 6: Agenda
Agenda Action Plan 2025 – The data-driven R&D Autobahn to Cures Our business strategy Data-driven precision medicine iPSC – Witnessing a new paradigm From J.HALSM to J.POD® AI/ML-driven integrated process from discovery to commercial manufacturing of biologics BRIDGEs From academic translation to pa
Slide 7: "The sharing economy principles will bring down attrition massively."
“The sharing Economy principles will bring down attrition massively.“ Werner Lanthaler PAGE 7
Slide 8: Our strategic frameworks
Action Plan 2025 – The data-driven R&D Autobahn to Cures Our strategic frameworks 2025 2021 2018 2012 Action Plan 2025 2009 Leadership in data, science, Action Plan 2022 multimodality & access Action Plan 2016 Aspire global leadership Action Plan 2012 Build Innovation seeds Restructure for growth PA
Slide 9: Action Plans deliver significant value
Action Plans deliver significant value Action Plans in numbers 2025 2021 2018 2012 Action Plan 2025 2009 Leadership in data, science, Action Plan 2022 multimodality & access Action Plan 2016 Aspire global leadership Action Plan 2012 Build innovation seeds Restructure for growth 2010 2015 2020 Reve
Slide 10: Ten years of growth are "… just the beginning"
Ten years of growth are “… just the beginning” Action Plans – Key Performance Indicators (KPI) 500 5,000 10yr CAGRs2) of KPIs Revenues: +25% 400 4,000 Adj. EBITDA: +50% R&D investments1): +40% 300 3,000 Co-owned projects: +35% Employees: +20% 200 2,000 100 1,000 0 0 2010 2011 2012 2013 201
Slide 11: Central infrastructures for better treatments
Central infrastructures for better treatments Our role in the Biotechnology ecosystem – Better healthcare; Access & more precise coverage Aging population challenges Life style / Dietary challenges Environmental challenges ~727 m persons aged 65+ ~463 m adults suffering from diabetes Air pollution k
Slide 12: Innovation hub that meets industry needs
Innovation hub that meets industry needs Value chain evolution Old model Fixed-cost Integrated but inefficient; Fixed-cost discovery & In-house front-end R&D clinical trials Blockbuster focus, high fixed development platforms platforms cost, low flexibility Current models Mid-size Pharma Incubators
Slide 13: Evotec's founding vision
Bringing the industry closer together, to learn faster together Evotec’s founding vision „The goal of evolution is not one single human as such, it is mankind.“ Manfred Eigen 1927–2019, Co-founder of Evotec, Nobelprize 1967 PAGE 13 Source: Allianz, Handelsblatt Juli 2020
Slide 14: Macrotrends support vision of precise and accessible drugs
Macrotrends support vision of precise and accessible drugs Growth drivers for the future RNA analysis/transcriptomics market1) Global AI market in drug discovery2) in US$ bn in US$ bn 8.7 20.0 CAGR 4.5 ~14% CAGR ~96% 0.7 2020 2025(e) 2020 2025(e) Global drug discovery external innovation market3) Gl
Slide 15: Multimodality increasingly opens new doors to cures
Multimodality increasingly opens new doors to cures Small molecules, biologics, cell and gene therapy Global biologics market1) Global gene therapy market2) in US$ bn in US$ bn 559 5.2 CAGR CAGR 317 ~12% 2.1 ~20% 2020 2025(e) 2020 2025(e) Global antisense & RNAi therapeutic market3) Global stem-cell
Slide 16: Data & science to deliver speed and higher predictive efficacy
Data & science to deliver speed and higher predictive efficacy Eight building blocks of the data-driven R&D Autobahn to Cures PAGE 16
Slide 17: Molecular disease profiles and AI/ML drive paradigm shift
Molecular disease profiles and AI/ML drive paradigm shift Disease relevance is paramount to change clinical success rates1) Drug Drug Clinical IND enabling Market screening optimisation development Current “One drug fits all” paradigm 90% of drugs Disease Target driven / Target Efficacy Safety are e
Slide 18: What we offer – Key growth drivers
Leadership in efficiency, data, science, multimodality and access What we offer – Key growth drivers for high-impact and high-value business R&D efficiency From high quality stand-alone EVOequity & EVOroyalty platforms1) services to EVOiR&D AI/ML & Precision From molecular platforms via iPSCs medici
Slide 19: Clearly defined work packages allow increased access
Clearly defined work packages allow increased access Capabilities & expertise overview Industry needs Capabilities & expertise create multimodality & data-driven R&D Autobahn for growth R&D efficiency platforms1) Target ID & Hit Sample DMPK & Research Bio In vivo In vivo Biomarker Integrated Lead va
Slide 20: Novelty, precision, and excellent execution drive co-ownership
Novelty, precision, and excellent execution drive co-ownership Unique business model R&D efficiency platforms R&D and IP 1 Integrated drug discovery contributing to key inventive steps generation Co-owned pipeline Indication-driven target pipelines 2 Novel targets P2X3, B1, A2a, … Just – Evotec Biol
Slide 21: "The Iceberg" is constantly growing and gaining visibility
„The Iceberg“ is constantly growing and gaining visibility >200 proprietary projects Onco Protein Metabolic Partner Neuroscience & Pain1) degrad. Oncology Diseases / Kidney Inflammation & Immunology Virology / Infectious Diseases (Selection) Ph3 Insomnia Ph2 CC - P2X3 NP– P2X3 OAB–P2X3 ND Endo-P2X3
Slide 22: > 200 proprietary projects in key disease areas
> 200 proprietary projects in key disease areas Broad and deep pipeline of product opportunities Number of drug development candidates in pipeline per indication Neuroscience 24 12 3 6 45 Oncology 9 20 15 17 61 Metabolic Disease 7 13 6 4 30 Inflammation & Immunology 13 1 16 6 36 + Women’s Health Inf
Slide 23: "Evotec Inside" – Fully invested pipeline gaining visibility
“Evotec Inside” – Fully invested pipeline gaining visibility Progress of drug candidates in advanced stages Molecule Therapeutic Area/Indication Partner Discovery Pre-clinical Phase I Phase II Phase III EVT201 Insomnia (GABA-A) Selected pipeline events BAY-1817080 BAY-1817080 BAY-1817080 Chronic cou
Slide 24: Building a massive co-owned clinical pipeline
Building a massive co-owned clinical pipeline EVT Innovate pipeline evolution 2015-2025 (e) 2015 20211)3) 2025(e)2)3) # of projects # of projects anticipated # of projects >170 >130 1 0 5 >100 12 9 >100 49 34 9 2 0 0 4 Platf. & Pre- Phase Phase Phase Appro- Total Platf. & Pre- Phase Phase Phase Appr
Slide 25: Our data-driven R&D Autobahn to success
Our data-driven R&D Autobahn to success Summary Integration drives differentiation Knowledge, experience and know-how creates success loop in research, discovery and development, high performance and inventive steps AI/ML predictions drive precision and speed Creating and exploiting data in optimise
Slide 26: Data-driven precision medicine iPSC – Witnessing a new paradigm
Data-driven precision medicine iPSC – Witnessing a new paradigm World-leading iPSC platform enabling transformative therapeutic concepts PAGE 26
Slide 27: Agenda
Agenda Action Plan 2025 – The data-driven R&D Autobahn to Cures Our business strategy Data-driven precision medicine iPSC – Witnessing a new paradigm From J.HALSM to J.POD® AI/ML-driven integrated process from discovery to commercial manufacturing of biologics BRIDGEs From academic translation to pa
Slide 28: "Patient-derived disease models are the new standard"
“Patient-derived disease models are the new standard of prediction-driven drug discovery.“ Cord Dohrmann PAGE 28
Slide 29: Precision medicine is our focus
Precision medicine is our focus Patient databases & models combined with EVOpanHunter/EVOpanOmics & Multi-modality Molecular patient Patient (iPSC) – derived Diagnostics and databases disease models biomarkers Re-defining health and Focus on disease relevance Precision diagnostics disease via
Slide 30: "iPSC modelling is the road to success for devastating diseases."
“iPSC modelling is the road to success for devastating diseases.“ Sandra Lubitz PAGE 30
Slide 31: iPSC technology shifts the drug discovery paradigm
iPSC technology shifts the drug discovery paradigm Focus on disease relevance from the start Hit Lead Target ID/ Pre-clinical identi- optimi- Phase I Phase II Phase III Approval Market validation development fication sation Con- Limited disease relevance High attrition rate Limited disease ventional
Slide 32: World leading iPSC drug discovery platform
World leading iPSC drug discovery platform Industrial scale manufacturing with best-in-class quality Patient specific iPSC Disease-affected cell types 384-well plates Large iPSC Optimised differentiation Large scale cell Disease modelling iPSC bank expansion protocols for desired cell types manufact
Slide 33: Diverse human disease models established for drug discovery
Diverse human disease models established for drug discovery Highest quality control standards applied for cell manufacturing Broad panel of cell types ZO-1 Quality control Microglia Motor neurons Batch testing Cortical neurons Specific markers Dopaminergic neurons Sterility testing P
Slide 34: >300 patient-derived validated iPSC lines
>300 patient-derived validated iPSC lines Broad panel of disease-specific genotypes for patient stratification iPSC High quality iPSC generation 25 38 bank Standardised patient consents 17 50 Standardised protocols Amyotrophic lateral sclerosis 27 Highest QC standards Frontotemporal dementia
Slide 35: A growing iPSC tool box to revolutionise pre-clinical development
A growing iPSC tool box to revolutionise pre-clinical development Modelling human disease in 2D and 3D Isogenic controls Co-cultures Disease-causing mutations inserted or Combining different iPSC-derived corrected via genetic modification cell types to study multicellular Perfect control to detect d
Slide 36: "Precision medicine enables more effective therapies for CNS diseases."
“Precision medicine enables more effective therapies for CNS diseases.“ Rainer Kuhn PAGE 36
Slide 37: Modelling nephron function with an organ-on-a-chip iPSC model
Modelling nephron function with an organ-on-a-chip iPSC model Culturing iPSC-derived kidney cells in microfluidic chips Albuminuria is a hallmark of chronic kidney Nephron-on-a-chip disease Glomerulus-on-a-chip Proximal tubule-on-a-chip Albumin filtered through glomeruli and reabsorbed at the pr
Slide 38: Modelling neuroinflammation in triple culture iPSC models
Modelling neuroinflammation in triple culture iPSC models Triple cultures reveal changes in microglia gene expression not observed in monoculture Healthy brain Diseased brain Quiescent Activated astrocyte astrocyte Resident Activated microglia microglia Hallmarks of neuroinflammation Elevation of
Slide 39: iPSC models to target retinal dystrophies
iPSC models to target retinal dystrophies Reversion phenotype screens of molecular signatures in RPE-associated retinal dystrophies Retinal pigment epithelial (RPE) cell degeneration is a main driver of many retinal diseases Highly efficient and robust iPSC-derived RPE disease models for Age-r
Slide 40: Large scale "clinical trial in a dish" models
Patient stratification guides decision on clinical trial design Identifying responder and non-responder populations for selected drugs Identifying molecular disease signature Large scale “clinical trial in a dish” models Patient Controls Patient cohort Molecular signature Molecular signature iPSCs D
Slide 41: The iPSC platform offers numerous partnering opportunities
The iPSC platform offers numerous partnering opportunities High-level overview on actionable disease areas Partnered areas Drug discovery options Neurodegenerative Disease Neuroinflammation Lysosomal Storage Diseases Chronic Kidney Disease Reversion phenotype screening Cortical neurons Cortical
Slide 42: Slide 42
Slide 43: From J.HALS to J.POD: Creating the biologics lane
From J.HALSM to J.POD® Creating the biologics lane on the multi-modality Autobahn Using the power of data science to deliver enhanced speed, lower cost and predictive efficacy PAGE 43
Slide 44: Agenda
Agenda Action Plan 2025 – The data-driven R&D Autobahn to Cures Our business strategy Data-driven precision medicine iPSC – Witnessing a new paradigm From J.HALSM to J.POD® AI/ML-driven integrated process from discovery to commercial manufacturing of biologics BRIDGEs From academic translation to pa
Slide 45: "The combination of data generation and AI/ML exploitation has transformational power."
“The combination of data generation and AI/ML exploitation has transformational power.“ Craig Johnstone PAGE 45
Slide 46: Taking a systems approach to rapid development of antibodies
Taking a systems approach to rapid development of antibodies Molecular similarity of antibodies provided the opportunity to standardise methods Manufacturing Discovery High-Speed Autobahn network Library Abacus PAGE 46
Slide 47: Systems approach creates continuous learning from data
Systems approach creates continuous learning from data Integrating molecular, process and manufacturing design delivers excellence in vivo AI generated Abacus and in vivo optimisation discovery to fit process development Robotic high-throughput process development Dynamic predictive process control
Slide 48: "Technological innovations are improving biotherapeutic access"
“Technological innovations are improving biotherapeutic access through cost and timeline reductions.“ Dean Pettit PAGE 48
Slide 49: Generating novel, humanoid antibody sequences with AI/ML
Generating novel, humanoid antibody sequences with AI/ML Overview of J.HALSM GAN methodology GAN methodology (Real) Humanoid antibody Discriminator – lightly trained on human Training Sequences Discriminator antibodies OAS set – EVQLQE … VEIKR > 1 million QVQLQQ … VEIKR QVQLVE … VEIKR Generator
Slide 50: Case study: Panning for hits on SARS-CoV-2
Case study: Panning for hits on SARS-CoV-2 Validation of J.HALSM through hit finding on SARS-CoV-2 (Wuhan) and B.1.1.7 (UK) variant SARS-CoV-2 Phage ELISA Three rounds of Phage Library panning conducted Phage particle 176 clones Wuhan binder sequenced Phage X Wuhan + B.1.1.7 binder Non-specific
Slide 51: Antibodies from other sources can also be improved by design
Antibodies from other sources can also be improved by design Abacus – an in silico computational toolset including ML algorithms Antibodies from various Abacus Antibody Fv with hot spots displayed Structure-based alignments Molecules optimised for sources1) Expression in cells Purification Germl
Slide 52: Modelling and intensifying high-yielding, robust processes
Modelling and intensifying high-yielding, robust processes Integration of proprietary reagents, robotics, ML modelling and miniaturisation Powerful expression vectors Custom media tuned for Connected downstream Highly stable formulation Optimised cell hosts productivity processing conditio
Slide 53: Disruptive, intensified process in simple modular clean rooms
Disruptive, intensified process in simple modular clean rooms J.POD® facility design reduces scale-up risk by scaling out, not up Intensified processing Production from a few kilograms to metric tons in the same facility PAGE 53
Slide 54: The time is now for J.POD EU
The time is now for J.POD® 2 EU … Rationale for J.POD® 2 EU in Toulouse, France1) J.POD® 1 US in Redmond is on track and demand is strong, including co-owned pipeline Europe is second largest biologics market, anticipated strong desire for local capacity and security of supply Toulouse footpri
Slide 55: Europe's first J.POD facility at Campus Curie
Europe’s first J.POD® facility at Campus Curie Aerial view of Campus Curie Suitable 2 ha. green-field site selected (red boxes)1) North end of existing Evotec Campus Curie, Toulouse, FR Design and planning started PAGE 55 1) Subject to local planning, environmental and building regulations and
Slide 56: Co-owned assets and J.POD capacity drive future value
Co-owned assets and J.POD® capacity drive future value Schematic representation of anticipated revenue and co-owned pipeline evolution over time >300 Co-owned Potential royalty-bearing Annual Revenue (m €) 2019 2020 2021 2022 2023 2024 2025 Acquisition of Just J.POD® 1 USA build J.POD® 2 EU build PA
Slide 57: The biotherapeutic fast lane on the "Autobahn"
The biotherapeutic fast lane on the “Autobahn" Summary – From J.HALSM to J.POD® A fast lane of end-to-end integrated offerings – from Concept to Proof of Concept … Cutting-edge mAb design technology and discovery capabilities Expanding capacity of disruptive, intensified, development and manufacture
Slide 58: BRIDGEs
BRIDGEs Delivering a paradigm-shift in academic translation PAGE 58
Slide 59: "BRIDGEs deliver a paradigm-shift in academic translation."
“BRIDGEs deliver a paradigm-shift in academic translation.“ Thomas Hanke PAGE 59
Slide 60: Agenda
Agenda Action Plan 2025 – The data-driven R&D Autobahn to Cures Our business strategy Data-driven precision medicine iPSC – Witnessing a new paradigm From J.HALSM to J.POD® AI/ML-driven integrated process from discovery to commercial manufacturing of biologics BRIDGEs From academic translation to pa
Slide 61: Academia remains key source for novel drugs
Academia remains key source for novel drugs Why developing a new paradigm to accelerate academic translation? Academia is major source of drug approvals … 15-20% 30-40% of approved drugs originate from academia1) of FDA approved were discovered in European academic labs2) … but translational efficie
Slide 62: BRIDGEs to accelerate translation are part of Action Plan 25
BRIDGEs to accelerate translation are part of Action Plan 2025 Our principles to create investable data sets from university starting points Identify the best starting points Industry experts to pick the most promising therapeutic concepts ‘among many’ Validate before investing Use Evotec’s technolo
Slide 63: Integrating most relevant expertise to accelerate translation
Integrating most relevant expertise to accelerate translation Value-adding contributions integrated by BRIDGE concept Status quo without BRIDGEs BRIDGE paradigm Scientific idea and early patent application Differentiated and proprietary starting points Capital used mainly for fix costs Capital used
Slide 64: New operational framework - BRIDGEs
New operational framework - BRIDGEs Alignment of strategic objectives and smooth integration of processes required Project proposals BRIDGE funding JSC1) Technological and NewCo / Acquisition biological validation Licensing Awarded projects Pre-agreed rights PAGE 64 1) Joint Steering Committee
Slide 65: BRIDGEs produce future multiple investment options
BRIDGEs produce future multiple investment options Creating long-term optionality with efficient translation Basic Applied Technology Development Product Commercialisation Market Entry & Research Research and Demonstration and Market Development Market Volume Public Market Funding Level Pension Plan
Slide 66: Oxford BRIDGE 'LAB282' as blueprint
Oxford BRIDGE ‘LAB282’ as blueprint Collaboration with Oxford University and OSI considered ‘best-in-class’ since 11/2016 Projects: Status Q1 2021 KPI2) achieved First-in-class 3-6 NewCo’s therapeutics >15 Stakeholders Successful projects2) Funding: 44 1) Awards granted £ 17m for 5+ years >60 Applic
Slide 67: 2-4x Acceleration based on only variable costs
2- 4x Acceleration based on only variable costs Re-defining translational efficiency: Example LAB282 Average project evaluation time Average time until first experiment Average time until conclusion of (in months before decision) (in weeks after decision) experiments (in months after start) -4x -3x
Slide 68: Academic starting points fit to our strategy and capabilities
Academic starting points fit to our strategy and capabilities The ‘wide net’ to generate robust data and options Cancer 2% 5% Hit ID Autoimmunity / inflammation 2% Hit ID (HTS) 7% 2% 2% Infectious disease 12% H2L Neurology 31% 30% Target validation Cardio-vascular disease 10% Hit ID (virtual screen)
Slide 69: BRIDGE contribution to co-owned pipeline just starting
BRIDGE contribution to co-owned pipeline just starting Projects with big financial upside Onco Protein Metabolic Partner Neuroscience & Pain degrad. Oncology Diseases / Kidney Inflammation & Immunology Virology / Infectious Diseases (Selection) Ph3 Insomnia Ph2 CC - P2X3 NP– P2X3 OAB–P2X3 ND Endo-P2
Slide 70: beLAB2122 exemplifies next-generation BRIDGE
beLAB2122 exemplifies next-generation BRIDGE Accessing unique cluster of top-tier academic institutions in Germany together with BMS Academic partner German Cancer Research Center (‘DKFZ’), the Goethe University Frankfurt, Heidelberg University and University of Tübingen Pharma partner Bristol Myers
Slide 71: First LAB282 company spun out in 2020
First LAB282 company spun out in 2020 Dark Blue Therapeutics developing multiple oncology projects Objective Develop successful LAB282 oncology projects towards clinical PoC1) Science Portfolio of promising single-target small molecule oncology projects (each at H2L stage, exciting biology and sound
Slide 72: BRIDGE spin-outs will complement current equity portfolio
BRIDGE spin-outs will complement current equity portfolio Growing portfolio of co-owned opportunities with operational synergies At equity investments (share ≥ 20% or significant influence) Joint Venture Equity participation Spin-off Equity participation Equity participation Spin-off Equity particip
Slide 73: Global BRIDGE aspiration aligned with Action Plan 2025
Global BRIDGE aspiration aligned with Action Plan 2025 Targeted development from 2021 … to 2025 Active academic partners Project proposals reviewed Projects completed in # in # per annum in total # 28 ~50 ~200 ~400 60 ~140 Investable data sets created Capital invested in projects Companies co-founde
Slide 74: Financials: Guard rails of Action Plan 2025
Financials Guard rails of Action Plan 2025 PAGE 74
Slide 75: "Taking advantage of low cost of capital will accelerate growth and returns."
“Taking advantage of low cost of capital will accelerate growth and returns.“ Enno Spillner PAGE 75
Slide 76: Agenda
Agenda Action Plan 2025 – The data-driven R&D Autobahn to Cures Our business strategy Data-driven precision medicine iPSC – Witnessing a new paradigm From J.HALSM to J.POD® AI/ML-driven integrated process from discovery to commercial manufacturing of biologics BRIDGEs From academic translation to pa
Slide 77: Degree of growth depends on co-owning and investment strategy
Degree of growth depends on co-owning and investment strategy Goal is to achieve group revenues > EUR 1,000 m by 2025 Targeted revenue development Overall growth subject to degree of co-ownership Just – Evotec Biologics: Goal to reach ~ 30% of group revenues (2020: ~10%) 5-yr CAGR 2020-2025 >15%
Slide 78: Innovative platforms and commercial manufacturing gain strength
Innovative platforms and commercial manufacturing gain strength Goal is to achieve a more balanced revenue mix at significantly higher volume by 2025 Revenue composition 2020 Revenue composition 2025 ~20% >25% ~10% ≥2x >30% ~70% >40% EVT Execute Just – Evotec EVT Innovate EVT Execute Just – Evotec E
Slide 79: Commitment to innovation expected to drive growth & profitability
Commitment to innovation expected to drive growth & profitability Targeting adjusted EBITDA ≥ EUR 300 m by 2025 Targeted adjusted EBITDA development 5-year adj. EBITDA CAGR 2020-2025 to reach at least 25% due to Operating leverage of broader platform and expanded manufacturing 5-yr CAGR capabiliti
Slide 80: Targeted adj. EBITDA margin expansion of at least 800 basis points
Targeted adj. EBITDA margin expansion of at least 800 basis points Aspiration of sustained adj. EBITDA margin ≥30% Targeted adjusted EBITDA margin development Anticipated adj. EBITDA drivers: Scale to yield further efficiency gains 35% Growing share of revenues from 30% manufacturing to translat
Slide 81: More to come …
More to come … Royalty generation from co-owned assets is “… just at the beginning” Potential revenue development of EVOroyalty EVOroyalty likely to remain at steady state throughout the majority of years covered by AP 2025 … … but to make a bigger impact long- term First approvals of co-owned a
Slide 82: Our mid-term aspirations at a glance
Our mid-term aspirations at a glance 2020-2025e Key Performance Indicator goals Revenues Adjusted EBITDA1) in € m in € m >100% ≥180% 500.9 >1,000 106.6 ≥300 Unpartnered R&D Co-owned projects2) >100% >100% 47 >100 118 >250 PAGE 82 1) before significant royalties 2) incl. Equity participations
Slide 83: Summary: Action Plan 2025
Al\ Piiiitotool) [IL ACTION PLAN 2025 The data-driven R&D Autobahn to Cures
Slide 84: Please join us on the data-driven R&D Autobahn to Cures
Please join us on the data-driven R&D Autobahn to Cures Eight building blocks of the data-driven R&D Autobahn to Cures PAGE 84
Slide 85: The Innovation hub in discovery & development
The Innovation hub in discovery & development Summary Precision medicine is paramount Disease relevance from the beginning will redefine “drug hunting” process – Action Plan 2025 is defining this core principle for its network of partners ML & AL will increase R&D IRR Unbiased application of rig
Slide 86: Questions and Answers
Slide 87: Many thanks for your participation!
Many thanks for your participation! Evotec SE, Capital Markets Day, April 20th 2021